Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/38015
Title: Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
Authors: Major, Rupert W.
Oozeerally, Issaam
Dawson, Simon
Riddleston, Helen
Gray, Laura J.
Brunskill, Nigel J.
First Published: 10-Jun-2016
Publisher: Elsevier
Citation: Atherosclerosis, 2016, 251, pp. 177-182
Abstract: BACKGROUND AND AIMS: Chronic kidney disease is a strong independent predictor of cardiovascular disease. No published meta-analyses on the use of aspirin for the primary prevention of cardiovascular disease in chronic kidney disease exist. We therefore performed a systematic review and meta-analysis of this subject. METHODS: We used a pre-defined and registered protocol (PROSPERO identification CRD42014008860). We searched Medline and Embase between 1996 and July 2015. Inclusion criteria were adult subjects with non-endstage chronic kidney disease (CKD) and no history of cardiovascular disease. The co-primary outcomes were major cardiovascular events and all-cause mortality. Secondary outcomes included bleeding-related events. We used a random effects model to pool data. RESULTS: Three trials were identified and two of these provided previously unpublished data. The studies included 4468 participants and 16,740 person-years of follow-up. There were no statistically significant reductions in the risk of major cardiovascular events (RR 0.92, 95% CI 0.49 to 1.73, p = 0.79, I(2) 71%) or mortality (RR 0.74, 95% CI 0.55 to 1.00, p = 0.05, I(2) 0%) with aspirin compared to the control group. Major bleeding events were increased with aspirin though (RR 1.98, 95% CI 1.11 to 3.52, p = 0.02, I(2) 0%). CONCLUSIONS: There is no clear benefit of aspirin for the primary prevention of cardiovascular events in CKD and no statistically significant reduction in mortality. Aspirin is likely to increase the risk of major bleeding events. Currently, insufficient randomised control trial data exists to recommend universal use or avoidance of aspirin for primary prevention of cardiovascular events in CKD.
DOI Link: 10.1016/j.atherosclerosis.2016.06.013
ISSN: 0021-9150
eISSN: 1879-1484
Links: http://www.sciencedirect.com/science/article/pii/S0021915016302581
http://hdl.handle.net/2381/38015
Embargo on file until: 10-Jun-2017
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2016, Elsevier. Deposited with reference to the publisher’s archiving policy available on the SHERPA/RoMEO website.
Description: The file associated with this record is under a 12 month embargo from publication in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
Aspirin-IRIS.pdfPost-review (final submitted author manuscript)505.77 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.